BFA
ITCI

BlackRock Fund Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BlackRock Fund Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$30.7M Buy
2,034,263
+939,045
+86% +$13.3M 0.01% 1956
2016
Q3 		$16.7M Buy
1,095,218
+52,118
+5% +$2.11M ﹤0.01% 2169
2016
Q2 		$40.5M Buy
1,043,100
+72,160
+7% +$2.59M 0.01% 1631
2016
Q1 		$27M Buy
970,940
+24,482
+3% +$816K 0.01% 1817
2015
Q4 		$50.9M Buy
946,458
+59,661
+7% +$3.01M 0.01% 1454
2015
Q3 		$35.5M Sell
886,797
-104,989
-11% -$3.42M 0.01% 1635
2015
Q2 		$31.7M Buy
991,786
+14,840
+2% +$376K 0.01% 1820
2015
Q1 		$23.3M Buy
976,946
+498,212
+104% +$11.2M 0.01% 1986
2014
Q4 		$8.45M Buy
478,734
+73,388
+18% +$1.15M ﹤0.01% 2559
2014
Q3 		$5.56M Sell
405,346
-16,647
-4% -$250K ﹤0.01% 2686
2014
Q2 		$7.12M Buy
+421,993
New +$6.97M ﹤0.01% 2623

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's ITCI Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Intra-Cellular Therapies Inc. (ITCI) stake by 86% in Q4 2016, buying an estimated $13.3M and bringing the position to 2,034,263 shares worth $30.7M. The position accounts for 0.01% of the portfolio, ranked #1956.

BlackRock Fund Advisors first reported a position in ITCI in Q2 2014 and has held it in 11 quarters since. The position peaked at $50.9M in Q4 2015. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

  • BlackRock Fund Advisors held 2,034,263 shares of Intra-Cellular Therapies Inc. worth $30.7M as of Q4 2016.
  • BlackRock Fund Advisors bought 939,045 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $13.3M.
  • Intra-Cellular Therapies Inc. made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1956 holding.
  • BlackRock Fund Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and has held it in 11 quarters since.
  • BlackRock Fund Advisors's Intra-Cellular Therapies Inc. position peaked at $50.9M in Q4 2015.
  • 129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.